IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Author's Avatar
Jun 02, 2023

– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients –